151 related articles for article (PubMed ID: 8105859)
1. Clinical trials referral resource. Clinical trials with Docetaxel (Taxotere).
Cheson BD; Arbuck SG; Phillips PH
Oncology (Williston Park); 1993 Sep; 7(9):51-2. PubMed ID: 8105859
[No Abstract] [Full Text] [Related]
2. Docetaxel (Taxotere) for advanced breast cancer.
Med Lett Drugs Ther; 1996 Sep; 38(984):87-8. PubMed ID: 8828520
[No Abstract] [Full Text] [Related]
3. The clinical rationale for developing docetaxel (Taxotere).
Armand JP
Anticancer Drugs; 1996 Aug; 7 Suppl 2():37-9. PubMed ID: 8862710
[TBL] [Abstract][Full Text] [Related]
4. Docetaxel (Taxotere): a new anti-cancer drug with promising potential?
Verweij J
Br J Cancer; 1994 Aug; 70(2):183-4. PubMed ID: 7914419
[No Abstract] [Full Text] [Related]
5. The development of docetaxel (Taxotere) in non-small cell lung cancer.
Kris MG; Miller VA; Ng KK; Grant SC
Semin Oncol; 1997 Aug; 24(4 Suppl 14):S14-1-S14-4. PubMed ID: 9335515
[No Abstract] [Full Text] [Related]
6. Docetaxel (Taxotere): preclinical and general clinical information.
Earhart RH
Semin Oncol; 1999 Oct; 26(5 Suppl 17):8-13. PubMed ID: 10604262
[TBL] [Abstract][Full Text] [Related]
7. Docetaxel: assessing a range of activity.
Aapro M; Rowinsky E
Anticancer Drugs; 2001 Feb; 12 Suppl 1():S1-3. PubMed ID: 11340897
[No Abstract] [Full Text] [Related]
8. Weekly schedules of docetaxel.
Burris H
Semin Oncol; 1998 Dec; 25(6 Suppl 13):21-3. PubMed ID: 9865688
[TBL] [Abstract][Full Text] [Related]
9. The taxoids: paclitaxel (Taxol) and docetaxel (Taxotere).
Pazdur R; Kudelka AP; Kavanagh JJ; Cohen PR; Raber MN
Cancer Treat Rev; 1993 Oct; 19(4):351-86. PubMed ID: 8106152
[TBL] [Abstract][Full Text] [Related]
10. [Taxanes: a breakthrough in cancer chemotherapy].
Inbar M; Merimsky O; Chaitchik S
Harefuah; 1997 Jul; 133(1-2):31-6. PubMed ID: 9332055
[No Abstract] [Full Text] [Related]
11. The scientific rationale for developing taxoids.
Aapro M
Anticancer Drugs; 1996 Aug; 7 Suppl 2():33-6. PubMed ID: 8862709
[TBL] [Abstract][Full Text] [Related]
12. In the clinic: where paclitaxel and docetaxel stand.
McNeil C
J Natl Cancer Inst; 1995 Aug; 87(15):1107. PubMed ID: 7674312
[No Abstract] [Full Text] [Related]
13. Conclusion: the place of docetaxel (Taxotere) in future therapy.
Khayat D
Anticancer Drugs; 1996 Aug; 7 Suppl 2():53. PubMed ID: 8862713
[No Abstract] [Full Text] [Related]
14. Emerging role of docetaxel (Taxotere) in the adjuvant therapy of breast cancer.
Ravdin PM
Semin Oncol; 1999 Jun; 26(3 Suppl 9):20-3. PubMed ID: 10426455
[TBL] [Abstract][Full Text] [Related]
15. Taxoids in head and neck cancer: the American approach.
Forastiere AA
Acta Otorhinolaryngol Belg; 1999; 53(3):253-7. PubMed ID: 10635404
[TBL] [Abstract][Full Text] [Related]
16. Taxoids: effective agents in anthracycline-resistant breast cancer.
Ravdin PM
Semin Oncol; 1995 Dec; 22(6 Suppl 13):29-34. PubMed ID: 8604450
[TBL] [Abstract][Full Text] [Related]
17. [Taxotere in various solid tumors].
Orel NF
Vopr Onkol; 1998; 44(5):639-44. PubMed ID: 9925501
[No Abstract] [Full Text] [Related]
18. Role of taxanes in adjuvant therapy.
Münster PN; Hudis CA
Cancer Invest; 2000; 18(1):32-8. PubMed ID: 10701365
[No Abstract] [Full Text] [Related]
19. Paclitaxel and docetaxel in breast and ovarian cancer.
Drug Ther Bull; 1997 Jun; 35(6):43-6. PubMed ID: 9282422
[TBL] [Abstract][Full Text] [Related]
20. Taxotere becomes first drug to outperform Adriamycin.
Ir Med J; 1997; 90(4):156. PubMed ID: 9267101
[No Abstract] [Full Text] [Related]
[Next] [New Search]
